It’s an additional option for people who’ve already tolerated 2.4 mg for at least a month and want more weight loss.
Key takeaways
- Wegovy’s standard titration runs 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over about 16 weeks, in 4-week steps.
- Wegovy HD (7.2 mg) was FDA-approved in March 2026, based on trial data showing about 20.7% average weight loss versus roughly 17.5% on the standard 2.4 mg dose.
- HD is only for patients who’ve already tolerated 2.4 mg for at least 4 weeks and need additional weight loss. It’s not a faster path to results for new patients.
- 1.7 mg is itself an FDA-approved maintenance dose, not just a step along the way, for people who can’t tolerate 2.4 mg.
The full Wegovy doses chart
| Dose | Role |
|---|---|
| 0.25 mg | Starting dose, weeks 1-4. Non-therapeutic; mainly reduces nausea once the dose increases. |
| 0.5 mg | Weeks 5-8. |
| 1.0 mg | Weeks 9-12. |
| 1.7 mg | Weeks 13-16. Also an FDA-approved maintenance dose on its own. |
| 2.4 mg | Standard maintenance dose, typically reached around week 17. |
| 7.2 mg (Wegovy HD) | New as of March 2026. Only after tolerating 2.4 mg for 4+ weeks, when additional weight loss is clinically appropriate. |
Each of the first five steps requires a minimum of 4 weeks before moving to the next. Your provider may hold you at a lower dose longer if side effects need more time to settle, or if you’re already getting the results you want at a lower dose.
What’s new about Wegovy HD
Wegovy HD was FDA-approved in March 2026 as a higher-dose option layered on top of the existing Wegovy lineup, not a replacement for it. It’s intended for people who’ve tolerated the standard 2.4 mg dose for at least 4 weeks and, in their provider’s judgment, would benefit from additional weight loss. In the trial that supported approval, people on 7.2 mg lost an average of about 20.7% of their starting body weight over 72 weeks, compared to roughly 17.5% on 2.4 mg and 2.4% on placebo.
The higher dose came with a notable increase in one particular side effect: dysesthesia, an altered or unusual skin sensation, was reported by about 22% of people on 7.2 mg compared to 6% on 2.4 mg. Overall safety was otherwise consistent with what’s already known about this class of medication. A single-dose pen for Wegovy HD was expected to launch in the U.S. in April 2026, so availability may still be catching up at some pharmacies.
You don’t have to reach the top of the ladder
There’s no requirement to progress all the way to 2.4 mg, let alone to HD. The 1.7 mg dose is itself FDA-approved as a maintenance dose, meaning some people stay there long-term if that’s what works for their body and goals. Whether to step up further is a conversation between you and your provider based on how you’re responding, not a fixed destination everyone is expected to reach.
Why the step-up schedule exists
Semaglutide, the active ingredient in Wegovy, has a long half-life of about a week, meaning it takes roughly 4 to 5 weeks for blood levels to fully stabilize after each dose change. The 4-week spacing between steps isn’t arbitrary; it’s built around how long the medication actually takes to reach a steady level in your system. Moving faster than the approved schedule mainly increases the risk of severe nausea and other GI side effects rather than speeding up results.
Who Wegovy is for
Wegovy is FDA-approved for adults with obesity, or adults who are overweight with at least one weight-related health condition such as high blood pressure, high cholesterol, or type 2 diabetes. It’s also approved to reduce the risk of major cardiovascular events, like heart attack and stroke, in adults with established heart disease who also have obesity or overweight. A licensed provider determines eligibility based on your BMI, health history, and any related conditions, not a chart alone.
Missed dose guidance
If you miss a dose, take it as soon as possible if it’s within 5 days of your scheduled injection day. If more than 5 days have passed, skip that dose and resume your regular weekly schedule at your next scheduled day rather than doubling up to make up for it. Consistency matters more than perfection here; a single missed dose handled correctly generally doesn’t derail overall progress.
Common side effects
Nausea, diarrhea, constipation, and reduced appetite are the most frequently reported side effects, especially in the days following a dose increase. These are usually mild to moderate and improve as your body adjusts to each step. Less common but more serious risks include gallbladder problems and pancreatitis, which is why ongoing check-ins with your provider matter throughout treatment.
Getting started
A licensed provider needs to evaluate your health history and weight loss goals before prescribing Wegovy at any dose, including whether HD is an appropriate next step if you’re already on 2.4 mg. At DermOnDemand, our board-certified providers review your information online and build a personalized treatment plan, typically within 24 hours, with prescriptions sent directly to your pharmacy when appropriate.
Frequently asked questions
Can I start directly on Wegovy HD?
No. HD is only appropriate after tolerating the 2.4 mg dose for at least 4 weeks. New patients still start at 0.25 mg and follow the standard titration.
Is Wegovy HD available everywhere yet?
It was approved in March 2026 with a U.S. launch expected shortly after in a single-dose pen. Availability can still vary by pharmacy as the rollout continues.
What if 2.4 mg is already working well for me?
There’s no requirement to move up to HD. It’s an option for people who want additional weight loss beyond what 2.4 mg is producing, not a default next step for everyone.
Ready to find out what’s right for you? Start an online consultation with DermOnDemand and get a personalized treatment plan, often within 24 hours. Learn more on our Wegovy page, or see pricing details here.
